Skip to content
OpenCapital
Get started

Mirum Pharmaceuticals, Inc. MIRM Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$159.9MBeat by $11.7M
EPS-$13.43Miss by $13.03
Revenue estimate$148.2M
EPS estimate-$0.40

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$166.0M
EPS estimate-$0.73

Financials

Q1 2026

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$6.96B+173%
Enterprise value$6.72B+183%
P/S12.2×+6.3×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%—

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Segments

By product

See full
Livmarli$113.8M+55.4%
Bile Acid Medicines$46.1M+20.1%

Versus estimates

Revenue

Q1 2026$159.9MBeat by $11.7M
Q4 2025$148.9MBeat by $6.4MQ3 2025$133.0MMiss by $7.9MQ2 2025$127.8MMiss by $2.3MQ1 2025$111.6MBeat by $13.2MQ4 2024$99.4MBeat by $2.8M

Diluted EPS

Q1 2026-$13.43Miss by $13.03
Q4 2025-$0.11Miss by $0.13Q3 2025$0.05Beat by $0.15Q2 2025-$0.12Beat by $0.19Q1 2025-$0.30Beat by $0.09Q4 2024-$0.49Miss by $0.22

Ask the moment Mirum Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Mirum Pharmaceuticals, Inc. report Q1 2026 earnings?
Mirum Pharmaceuticals, Inc. (MIRM) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Mirum Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Mirum Pharmaceuticals, Inc. reported revenue of $159.9M and eps of $-13.43 for Q1 2026.
Did Mirum Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $148.2M by $11.7M. EPS missed the consensus estimate of $-0.40 by $13.03.
How did Mirum Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 43.3% from $111.6M a year earlier and eps declined 4376.7% from $-0.30.
Where can I find Mirum Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-202609) and the 10-Q periodic report (0001759425-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.